Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob Djavan

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Annals of the New York Academy of Sciences|January 26, 2011
Chemopreventive effects of resveratrol and resveratrol derivativesThomas Szekeres, Philipp Saiko, Monika Fritzer-Szekeres, et al.
European Urology|January 1, 2003
PSA progression following radical prostatectomy and radiation therapy: new standards in the new MillenniumBob Djavan, Judd W Moul, Alexandre Zlotta, et al.
BJU International|June 28, 2007
Is the era of prostate-specific antigen over?Bob Djavan, Bernardo Rocco, Anton Stangelberger, et al.
Current Opinion in Urology|November 30, 2011
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisitedArmando A Juliao, Mauricio Plata, Amir Kazzazi, et al.
Current Opinion in Urology|November 10, 2012
Imaging in benign prostatic hyperplasia: what is new?Hamidreza Abdi, Amir Kazzazi, Soroush T Bazargani, et al.
BJU International|March 30, 2011
The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancerBob Djavan, Juliana Laze, Elisabeth Eckersberger, et al.
Urologia Internationalis|July 8, 2003
A prospective randomized study of combined visual laser ablation and transurethral resection of the prostate versus transurethral prostatectomy aloneBernhard Planz, Tomislav Kalem, Christian Sprenger, et al.
The Canadian Journal of Urology|August 26, 2010
Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancerBob Djavan, Peter Schlegel, Georg Salomon, et al.
The Canadian Journal of Urology|June 28, 2011
New findings in localized and advanced prostate cancer: AUA 2011 reviewAmir Kazzazi, Shabnam Momtahen, Aron Bruhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Novel artificial neural network for early detection of prostate cancerBob Djavan, Mesut Remzi, Alexandre Zlotta, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Annals of the New York Academy of Sciences|January 26, 2011
Chemopreventive effects of resveratrol and resveratrol derivativesThomas Szekeres, Philipp Saiko, Monika Fritzer-Szekeres, et al.
European Urology|January 1, 2003
PSA progression following radical prostatectomy and radiation therapy: new standards in the new MillenniumBob Djavan, Judd W Moul, Alexandre Zlotta, et al.
BJU International|June 28, 2007
Is the era of prostate-specific antigen over?Bob Djavan, Bernardo Rocco, Anton Stangelberger, et al.
Current Opinion in Urology|November 30, 2011
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisitedArmando A Juliao, Mauricio Plata, Amir Kazzazi, et al.
Current Opinion in Urology|November 10, 2012
Imaging in benign prostatic hyperplasia: what is new?Hamidreza Abdi, Amir Kazzazi, Soroush T Bazargani, et al.
BJU International|March 30, 2011
The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancerBob Djavan, Juliana Laze, Elisabeth Eckersberger, et al.
Urologia Internationalis|July 8, 2003
A prospective randomized study of combined visual laser ablation and transurethral resection of the prostate versus transurethral prostatectomy aloneBernhard Planz, Tomislav Kalem, Christian Sprenger, et al.
The Canadian Journal of Urology|August 26, 2010
Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancerBob Djavan, Peter Schlegel, Georg Salomon, et al.
The Canadian Journal of Urology|June 28, 2011
New findings in localized and advanced prostate cancer: AUA 2011 reviewAmir Kazzazi, Shabnam Momtahen, Aron Bruhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Novel artificial neural network for early detection of prostate cancerBob Djavan, Mesut Remzi, Alexandre Zlotta, et al.
Pageof 12